Metastat Inc

MetaStat Voluntarily Withdraws Listing on the OTCQB and Files Form 15 to Suspend its Reporting Obligations

MetaStat Presents Positive Data Showing Inhibition of the MENA-pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer

MetaStat Announces Positive Topline Data Showing Over 50% Reduction in Cancer Metastasis from Preclinical Studies Evaluating Inhibition of the MAPKAPK2 Kinase Pathway

MetaStat Announces Upcoming Investor and Pharmaceutical Industry Partnering Conference Presentations

MetaStat Welcomes Renato T. Skerlj, Ph.D., Accomplished Drug Developer to Its Scientific and Clinical Advisory Board